Aurobindo Pharma Ltd. is a high-risk pharmaceutical company based in India, with an ESG score of 32.2. Specializing in specialty and generic drug manufacturing, Aurobindo Pharma's product range covers a wide range of therapeutic areas. The majority of their sales come from the United States and Europe, primarily in the formulations business. They are open to mergers and acquisitions to expand their research, development, and marketing activities.